Good practice in the management of amyotrophic lateral sclerosis: Clinical guidelines. An evidence‐based review with good practice points. EALSC Working Group

References

• Abrahams S., Goldstein L. H., Kew J. J., Brooks D. J., Lloyd C. M., Frith C. D., et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain 1996; 119: 2105–20
   PubMed Web of Science ®Google Scholar
• Forsgren L., Almay B. G., Holmgren G., Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand 1983; 68: 20–9
   PubMed Web of Science ®Google Scholar
• Haverkamp L. J., Appel V., Appel S. H. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707–19
   PubMed Web of Science ®Google Scholar
• Bobowick A. R., Brody J. A. Epidemiology of motor neuron diseases. N Engl J Med 1973; 288: 1047–55
   PubMed Web of Science ®Google Scholar
• Ince P. G., Lowe J., Shaw P. J. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998; 24: 104–17
   PubMed Web of Science ®Google Scholar
• Brugman F., Wokke J. H., Vianney de Jong J. M., Franssen H., Faber C. G., van den Berg L. H. Primary lateral sclerosis as a phenotypic manifestation of familial ALS. Neurology 2005; 64: 1778–9
   PubMed Web of Science ®Google Scholar
• Andersen P. M., Borasio G. D., Dengler R., Hardiman O., Kollewe K., Leigh P. N., et al. EFNS Task Force on Management of Amyotrophic Lateral Sclerosis. Guidelines for diagnosing and clinical care of patients and relatives. An evidence‐based review with Good Practice Points. Eur J Neurol 2005; 12: 921–38
   PubMed Web of Science ®Google Scholar
• Brainin M., Barnes M., Baron J. C., Gilhus N. E., Hughes R., Selmaj K., et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces: revised recommendations 2004. Eur J Neurol 2004; 11: 577–81
   PubMed Web of Science ®Google Scholar
• Li T. M., Day S. J., Alberman E., Swash M. Differential diagnosis of motor neuron disease from other neurological conditions. Lancet 1986; 2: 731–3
   PubMedGoogle Scholar
• Wilbourn A. J. Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria. J Neurol Sci 1998; 160((Suppl 1))S25–9
   PubMed Web of Science ®Google Scholar
• Meininger V. Getting the diagnosis right: beyond El Escorial. J Neurol 1999; 246((Suppl 3))10–5
   Google Scholar
• Chio A. Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 1999; 246((Suppl 3))1–5
   Google Scholar
• Chio A. Update on ISI survey: Europe, North America and South America. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, Suppl 1: S9–11
   Google Scholar
• Bromberg M. Accelerating the diagnosis of amyotrophic lateral sclerosis. The Neurologist 1999; 5: 63–74
   Web of Science ®Google Scholar
• Aggarwal A., Nicholson G. Detection of preclinical motor neuron loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 2002; 73: 199–201
   PubMed Web of Science ®Google Scholar
• Dengler R., Tröger M. Impact of riluzole on the relationship between patient and physician. J Neurol 2001; 244((Suppl 2))S30–2
   Google Scholar
• Lima A., Evangelista T., de Carvalho M. Increased creatine kinase and spontaneous activity on electromyography, in amyotrophic lateral sclerosis. Electromyography and Clinical Neurophysiology 2003; 43: 189–92
   PubMedGoogle Scholar
• Evangelista T., Carvalho M., Conceicao I., Pinto A., de Lurdes M., Luis M. L. Motor neuropathies mimicking amyotrophic lateral sclerosis/motor neuron disease. J Neurol Sci 1996; 139((Suppl))95–8
   PubMedGoogle Scholar
• Traynor B. J., Codd M. B., Corr B., Forde C., Frost E., Hardiman O. Amyotrophic lateral sclerosis mimic syndromes. Arch Neurol 2000; 57: 109–13
   PubMed Web of Science ®Google Scholar
• Belsh J. M., Schiffman P. L. The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and it repercussions. J Neurol Sci 1996; 139((Suppl))110–6
   PubMed Web of Science ®Google Scholar
• Davenport R. J., Swingler R. J., Chancellor A. M., Warlow C. P. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1996; 60: 147–51
   PubMed Web of Science ®Google Scholar
• Brooks B. R. Earlier is better: the benefits of early diagnosis. Neurology 1999; 53((Suppl 5))S53–4
   Google Scholar
• Brooks B. R., Miller R. G., Swash M. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293–9
   PubMed Web of Science ®Google Scholar
• Ross M. A., Miller R. G., Berchert L., Parry G., Barohn R. J., Armon C., et al. Towards earlier diagnosis of ALS. Revised criteria. Neurology 1998; 50: 768–72
   PubMed Web of Science ®Google Scholar
• Leigh P. N., Abrahams S., Al‐Chalabi A., Ampong M. A., Goldstein L. H., Johnson J., , King's MND Care and Research Team, et al. The management of motor neuron disease. J Neurol Neurosurg Psychiatry 2003; 70((Suppl 4))32–47
   Google Scholar
• Lind S. E., Good M. D., Seidel S., Csordas T., Good B. J. Telling the diagnosis in cancer. J Clin Oncol 1989; 7: 583–9
   PubMed Web of Science ®Google Scholar
• Damian D., Tattersall M. H. N. Letters to patients: improving communication in cancer care. Lancet 1991; 338: 923–5
   PubMed Web of Science ®Google Scholar
• Doyle D. Breaking bad news. J Royal Soc Med 1996; 89: 590–1
   PubMed Web of Science ®Google Scholar
• Davies E., Hopkins A. Good practice in the management of adults with malignant cerebral glioma: clinical guidelines. Working Group. Br J Neurosurg 1997; 11: 318–30
   PubMed Web of Science ®Google Scholar
• Miller R. G., Rosenberg J. A., Gelinas D. F., Mitsumoto H., Newman D., Sufit R., et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence‐based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52: 1311–23
   PubMed Web of Science ®Google Scholar
• Borasio G. D., Sloan R., Pongratz D. E. Breaking the news in amyotrophic lateral sclerosis. J Neurol Sci 1998; 160((Suppl 1))S127–33
   Google Scholar
• McCluskey L., Casarett D., Siderowf A. Breaking the news: a survey of ALS patients and their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 131–5
   PubMed Web of Science ®Google Scholar
• Borasio G. D., Shaw P. J., Hardiman O., Ludolph A. C., Sales Luis M. L., Silani V., for the European ALS Study Group. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 159–64
   PubMed Web of Science ®Google Scholar
• Ackerman G. M., Oliver D. Psychosocial support in an outpatient clinic. Palliat Med 1997; 11: 167–8
   PubMed Web of Science ®Google Scholar
• Chio A., Silani V., Italian ALS Study Group. ALS care in Italy: a nationwide study in neurological centres. J Neurol Sci 2001; 191: 145–50
   PubMed Web of Science ®Google Scholar
• Howard R. S., Orrell R. W. Management of motor neuron disease. Postgrad Med J 2002; 78: 736–41
   PubMed Web of Science ®Google Scholar
• Traynor B. J., Alexander M., Corr B., Frost E., Hardiman O. Effects of a multidisciplinary ALS clinic on survival. J Neurol Neurosurg Psychiatry 2003; 74: 1258–61
   PubMed Web of Science ®Google Scholar
• Lee J. R. J., Annegers J. F., Appel S. Prognosis of ALS and the effects of referral selection. J Neurol Sci 1995; 132: 207–15
   PubMed Web of Science ®Google Scholar
• Chio A., Mora G., Balzarino C., Mutani R. Interdisciplinary ALS Centres: effect of survival and use of health services in a population‐based survey. Neurology 2004; 62((Suppl 5))S23.003, (Abstract 268)
   Google Scholar
• Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar
• Lacomblez L., Bensimon G., Leigh P. N., Guillet P., Meininger V. Dose‐ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425–31
   PubMed Web of Science ®Google Scholar
• Miller R. G., Mitchell J. D., Lyon M., Moore D. H. Riluzole for amyotrophic lateral sclerosis (ALS/motor neuron disease (MND). Cochrane Database Syst Rev 2002; 2: CD001447
   Google Scholar
• Brooks B. R., Belden D. S., Roelke K., Parnell J., Peper S., Houdek A., et al. Survival in non‐riluzole treated ALS patients is identical before and since 1996: a clinic‐based epidemiological study. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2((Suppl 2))60–61, (abstract P15)
   Google Scholar
• Turner M. R., Bakker M., Sham P., Shaw C. E., Leigh P. N., Al‐Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 15–21
   PubMed Web of Science ®Google Scholar
• Traynor B. J., Alexander M., Corr B., Frost E., Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis: a population‐based study in Ireland, 1996–2000. J Neurol 2003; 250: 473–9
   PubMed Web of Science ®Google Scholar
• Andersen P. M., Sims K. B., Xin W. W., Kiely R., O'Neill G., Ravits J., et al. Sixteen novel mutations in the gene encoding Cu/Zn‐superoxide dismutase in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 2: 62–73
   Web of Science ®Google Scholar
• Silani V., Cova L., Corbo M., Ciammola A., Polli E. Stem‐cell therapy for amyotrophic lateral sclerosis. Lancet 2004; 364: 200–2
   PubMed Web of Science ®Google Scholar
• Czaplinski A., Schweikert K., Strobel W., Steck A. J., Weber M. Symtomatische Therapie der amyotrophen lateralsklerose (ALS). Praxis 2006; 95: 263–71
   PubMedGoogle Scholar
• Forshew D. A., Bromberg M. B. A survey of clinicans' practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 258–63
   PubMedGoogle Scholar
• Hyson H. C., Johnson A. M., Jog M. S. Sublingual atropine for sialorrhoea secondary to Parkinsonism: a pilot study. Mov Disord 2002; 17: 1318–20
   PubMed Web of Science ®Google Scholar
• Mier R. J., Bachrach S. J., Lakin R. C., Barker T., Childs J., Moran M. Treatment of sialorrhoea with glycopyrrolate: a double‐blind, dose‐ranging study. Arch Pediatr Adolesc Med 2000; 154: 1214–8
   PubMedGoogle Scholar
• Talmi Y. P., Finkelstein Y., Zohar Y. Reduction of salivary flow in amyotrophic lateral sclerosis with Scopoderm TTS. Head Neck 1989; 11: 565
   PubMed Web of Science ®Google Scholar
• Talmi Y. P., Finkelstein Y., Zohar Y. Reduction of salivary flow with transdermal scopolamine: a four‐year experience. Otolaryngol Head Neck Surg 1990; 103: 615–8
   PubMed Web of Science ®Google Scholar
• Camp‐Bruno J. A., Winsberg B. F., Green‐Parsons A. R., Abrams J. P. Efficacy of benztropine therapy for drooling. Dev Med Child Neurol 1989; 31: 309–19
   PubMed Web of Science ®Google Scholar
• Tan E‐K. Botulinum toxin treatment of sialorrhoea: comparing different therapeutic preparations. Eur J Neurol 2006; 13((Suppl 1))60–4
   PubMedGoogle Scholar
• Giess R., Naumann M., Werner E., Riemann R., Beck M., Puls I., et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 121–3
   PubMed Web of Science ®Google Scholar
• Porta M., Gamba M., Bertacchi G., Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 2001; 70: 538–40
   PubMed Web of Science ®Google Scholar
• Dogu O., Apaydin D., Sevim S., Talas D. U., Aral M. Ultrasound‐guided versus ‘blind’ intraparotid injections of botulinum toxin‐A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004; 106: 93–6
   PubMed Web of Science ®Google Scholar
• Tan E‐K., Lo Y. L., Seah A., Auchus A. P. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 2001; 190: 95–7
   PubMed Web of Science ®Google Scholar
• Winterholler M. G., Erbguth F. J., Wolf S., Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side‐effects of a transductal approach. J Neurol Neurosurg Psychiatry 2001; 70: 417–8
   PubMed Web of Science ®Google Scholar
• Andersen P. M., Gronberg H., Frankzen L., Funegard U. External radiation of the parotid glands significantly reduces drooling in patients with motor neuron disease with bulbar paresis. J Neurol Sci 2001; 191: 111–4
   PubMed Web of Science ®Google Scholar
• Harriman M., Morrison M., Hay J., Revonta M., Eisen A., Lentle B. Use of radiotherapy for control of sialorrhoea in patients with amyotrophic lateral sclerosis. J Otolaryngol 2001; 30: 242–5
   PubMedGoogle Scholar
• Stalpers L. J., Moser E. C. Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology 2002; 58: 1308
   PubMed Web of Science ®Google Scholar
• Burton M. J. The surgical management of drooling. Dev Med Child Neurol 1991; 33: 1110–6
   PubMed Web of Science ®Google Scholar
• Hockstein N. G., Samadi D. S., Gendron K., Handler S. D. Sialorrhoea: a management challenge. Am Fam Physician 2004; 69: 2628–34
   PubMed Web of Science ®Google Scholar
• Janzen V. D., Rae R. E., Hudson A. J. Otolaryngologic manifestations of ALS. J Otolaryngology 1988; 17: 41–2
   PubMedGoogle Scholar
• Newall A. R., Orser R., Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996; 139((Suppl))43–4
   PubMed Web of Science ®Google Scholar
• Hanayama K., Ishikawa Y., Bach J. R. Amyotrophic lateral sclerosis: successful treatment of mucous plugging by mechanical insufflation‐exsufflation. Am J Phys Med Rehabil 1997; 76: 338–9
   PubMed Web of Science ®Google Scholar
• Sancho J., Servera E., Diaz J., Marin J. Efficacy of mechanical insufflation‐exsufflation in medically stable patients with amyotrophic lateral sclerosis. Chest 2004; 125: 1400–5
   PubMed Web of Science ®Google Scholar
• Gallagher J. P. Pathological laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989; 80: 114–7
   PubMed Web of Science ®Google Scholar
• Brooks B. R., Thisted R. A., Appel S. H., Bradley W. G., Olney R. K., Berg J. E., et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. The AVP‐923 ALS Study Group. Neurology 2004; 63: 1364–70
   PubMed Web of Science ®Google Scholar
• Iannaccone S., Ferini‐Strambi L. Pharmacological treatment of emotional lability. Clin Neuropharmacol 1996; 19: 532–5
   PubMed Web of Science ®Google Scholar
• Schiffer R. B., Herndon R. M., Rudick R. A. Treatment of pathological laughing and weeping with amitriptyline. N Engl J Med 1985; 312: 1480–2
   PubMed Web of Science ®Google Scholar
• Andersen G., Vestergaard K., Riis J. O. Citalopram for post‐stroke pathological crying. Lancet 1993; 342: 837–9
   PubMed Web of Science ®Google Scholar
• Poeck K. Pathologisches lachen und weinen bei bulber amyotrophischer lateralsklerose. Deutsche Med Wochenschr 1996; 94: 310–4
   Google Scholar
• Connolly P. S., Shirley E. A., Wasson J. H., Nierenberg D. W. Treatment of nocturnal leg cramps. A crossover trial of quinine vs. vitamin E. Arch Intern Med 1992; 152: 1877–80
   PubMedGoogle Scholar
• Diener H. C., Dethlefsen U., Dethlefsen‐Gruber S., Verbeek P. Effectiveness of quinine in treating muscle cramps: a double‐blind, placebo‐controlled, parallel‐group, multicentre trial. Int J Clin Pract 2002; 56: 243–6
   PubMed Web of Science ®Google Scholar
• Drory V. E., Goltsman E., Reznik J. G., Mosek A., Korczyn A. D. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 133–7
   PubMed Web of Science ®Google Scholar
• Kesiktas N., Paker N., Erdogan N., Gulsen G., Bicki D., Yilmaz H. The use of hydrotherapy for the management of spasticity. Neurorehabil Neural Repair 2004; 18: 268–73
   PubMed Web of Science ®Google Scholar
• dos Santos M. T., de Oliveira L. M. Use of cryotherapy to enhance mouth opening in patients with cerebral palsy. Spec Care Dentist 2004; 24: 232–4
   PubMedGoogle Scholar
• Norris FH J. r., U KS., Sachais B., Carey M. Trial of baclofen in amyotrophic lateral sclerosis. Arch Neurol 1979; 36: 715–6
   PubMedGoogle Scholar
• Marquardt G., Seifert V. Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 275–6
   PubMed Web of Science ®Google Scholar
• Rocha J. A., Reis C., Simoes F., Fonseca J., Mendes Ribeiro J. Diagnostic investigation and multidisciplinary management in motor neuron disease. J Neurol 2005; 252: 1435–47
   PubMed Web of Science ®Google Scholar
• Winterholler M. G., Heckmann J. G., Hecht M., Erbguth F. J. Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin. Neurology 2002; 58: 502–3
   PubMed Web of Science ®Google Scholar
• Dengler R. Current treatment pathways in ALS: a European perspective. Neurology 1999; 53: S4–10
   Web of Science ®Google Scholar
• Miller R. G. Examining the evidence about treatment in ALS/MND. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 3–7
   PubMed Web of Science ®Google Scholar
• Haberlandt W. F. Genetic aspects of amyotrphic lateral sclerosis and progressive bulbar paralysis. Acta Genet Med Gemell 1959; 8: 369–73
   PubMedGoogle Scholar
• Murros K., Fogelholm R. Amyotrophic lateral sclerosis in middle‐Finland: an epidemiological study. Acta Neurol Scand 1983; 67: 41–7
   PubMed Web of Science ®Google Scholar
• Thijs V., Peeters E., Theys P., Matthijs G., Robberecht W. Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta Neurol Belg 2000; 100: 84–90
   PubMed Web of Science ®Google Scholar
• Murray T. J., Pride S., Haley G. Motor neuron disease in Nova Scotia. Can Med Assoc J 1974; 110: 814–7
   PubMed Web of Science ®Google Scholar
• Gunnarsson L‐G., Palm R. Motor neuron disease and heavy labour: an epidemiological survey of Värmland county, Sweden. Neuroepidemiology 1984; 3: 195–206
   Google Scholar
• Li T‐M., Alberman E., Swash M. Comparison of sporadic and familial disease among 580 cases of motor neuron disease. J Neurol Neurosurg Psychiatry 1988; 51: 778–84
   PubMed Web of Science ®Google Scholar
• Rosen A. D. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol 1978; 35: 638–42
   PubMed Web of Science ®Google Scholar
• Giagheddu M., Puggioni G., Masala C., Biancu F., Pirari G., Piras M. R., et al. Epidemiological study of amyotrophic lateral sclerosis in Sardinia, Italy. Acta Neurol Scand 1983; 68: 394–404
   PubMed Web of Science ®Google Scholar
• Højer‐Pedersen E., Christensen P. B., Jensen N. B. Incidence and prevalence of motor neuron disease in two Danish counties. Neuroepidemiology 1989; 8: 151–9
   PubMed Web of Science ®Google Scholar
• Fong K. Y., Yu Y. L., Chan Y. W., Kay R., Chan J., Yang Z., et al. Motor neuron disease in Hong Kong Chinese: epidemiology and clinical picture. Neuroepidemiology 1996; 15: 239–45
   PubMed Web of Science ®Google Scholar
• Jokelainen M. Amyotrophic lateral sclerosis in Finland. II: Clinical characteristics. Acta Neurol Scand 1977; 56: 194–204
   PubMed Web of Science ®Google Scholar
• Andersen P. M., Forsgren L., Binzer M., Nilsson P., Ala‐Hurula V., Keranen M. L., et al. Autosomal recessive adult‐onset ALS associated with homozygosity for Asp90Ala Cu/Zn‐superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119: 1153–72
   PubMed Web of Science ®Google Scholar
• Corrado L., D'Alfonso S., Bergamaschi L., Testa L., Leone M., Nasuelli N., et al. SOD1 gene mutations in Italian patients with sporadic amyotrophic lateral sclerosis (ALS). Neuromuscul Disord 2006; 16: 800–4
   PubMed Web of Science ®Google Scholar
• Jones C. T., Swingler R. J., Simpson S. A., Brock D. J. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet 1995; 32: 290–2
   PubMed Web of Science ®Google Scholar
• Gellera C. Genetics of ALS in Italian families. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2((Suppl 1))S43–6
   Web of Science ®Google Scholar
• Andersen P. M., Nilsson P., Keranen M. L., Forsgren L., Hagglund J., Karlsborg M., et al. Phenotypic heterogeneity in MND patients with Cu/Zn‐superoxide dismutase mutations in Scandinavia. Brain 1997; 10: 1723–37
   Web of Science ®Google Scholar
• Shaw C. E., Enayat Z. E., Chioza B. A., Al‐Chalabi A., Radunovic A., Powell J. F., et al. Mutations in all five exons of SOD‐1 may cause ALS. Ann Neurol 1998; 43: 390–4
   PubMed Web of Science ®Google Scholar
• Jackson M., Al‐Chalabi A., Enayat Z. E., Chioza B., Leigh P. N., Morrison K. E. Copper/zinc superoxide dismutase 1 and sporadic amyotrophic lateral sclerosis: analysis of 155 cases and identification of a novel insertion mutation. Ann Neurol 1997; 42: 803–7
   PubMed Web of Science ®Google Scholar
• Garcia‐Redondo A., Bustos F., Juan Y Seva B., Del Hoyo P., Jimenez S., Campos Y., et al. Molecular analysis of the superoxide dismutase 1 gene in Spanish patients with sporadic or familial amyotrophic lateral sclerosis. Muscle Nerve 2002; 26: 274–8
   PubMed Web of Science ®Google Scholar
• Battistini S., Giannini F., Greco G., Bibbo G., Ferrera L., Marini V., et al. SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicentre Italian study. J Neurol 2005; 252: 782–8
   PubMed Web of Science ®Google Scholar
• Cudkowicz M. E., McKenna‐Yasek D., Sapp P. E., Chin W., Geller B., Hayden D. L., et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997; 41: 210–21
   PubMed Web of Science ®Google Scholar
• Boukaftane Y., Khoris J., Moulard B., Salachas F., Meininger V., Malafosse A., et al. Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can J Neurol Sci 1998; 25: 192–6
   PubMed Web of Science ®Google Scholar
• Niemann S., Joos H., Meyer T., Vielhaber S., Reuner U., Gleichmann M., et al. Familial ALS in Germany: origin of the R115G SOD1 mutation by a founder effect. J Neurol Neurosurg Psychiatry 2004; 75: 1186–8
   PubMed Web of Science ®Google Scholar
• Gasser T., Dichgans M., Finsterer J., Hausmanowa‐Petrusewicz I., Jurkat‐Rott K., Klopstock T., et al. EFNS task force on molecular diagnosis of neurological disorders. Part 1. Eur J Neurol 2001; 8: 299–314
   PubMedGoogle Scholar
• Lyall R. A., Donaldson N., Polkey M. I., Leigh P. N., Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124: 2000–13
   PubMed Web of Science ®Google Scholar
• Bourke S. C., Gibson G. J. Non‐invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 67–71
   PubMed Web of Science ®Google Scholar
• Annane D., Chevrolet J. C., Chevret S., Raphael J. C. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev 2000; CD001941
   Google Scholar
• Bourke S. C., Tomlinson M., Williams T. L., Bullock R. E., Shaw P. J., Gibson G. J. Effects of non‐invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial. Lancet Neurol 2006; 5: 140–7
   PubMed Web of Science ®Google Scholar
• Mustfa N., Walsh E., Bryant V., Lyall R. A., Addington‐Hall J., Goldstein L. H., et al. The effect of non‐invasive ventilation on ALS patients and their caregivers. Neurology 2006; 66: 1211–7
   PubMed Web of Science ®Google Scholar
• Cazzolli P. A., Oppenheimer E. A. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy‐intermittent positive pressure ventilation. J Neurol Sci 1996; 139((Suppl))123–8
   PubMed Web of Science ®Google Scholar
• Jennings A. L., Davies A. N., Higgins J. P., Gibbs J. S., Broadley K. E. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939–44
   PubMed Web of Science ®Google Scholar
• Bruera E., Sweeney C., Willey J., Palmer J. L., Strasser F., Morice R. C., et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnoea. Palliat Med 2003; 17: 659–63
   PubMed Web of Science ®Google Scholar
• Desport J. C., Preux P. M., Truong C. T., Courat L., Vallat J. M., Couratier P. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 91–6
   PubMed Web of Science ®Google Scholar
• Heffernan C., Jenkinson C., Holmes T., Feder G., Kupfer R., Leigh P. N., et al. Nutritional management in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 72–83
   PubMed Web of Science ®Google Scholar
• Mathus‐Vliegen L. M., Louwerse L. S., Merkus M. P., Tytgat G. N., Vianney de Jong J. M. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc 1994; 40: 463–9
   PubMed Web of Science ®Google Scholar
• Shaw A. S., Ampong M. A., Rio A., Al‐Chalabi A., Sellars M. E., Ellis C., et al. Survival of patients with ALS following institution of enteral feeding is related to pre‐procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler 2006; 7: 16–21
   PubMed Web of Science ®Google Scholar
• Chio A., Galletti R., Finocchiaro C., Righi D., Ruffino M. A., Calvo A., et al. Percutaneous radiologic gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry 2004; 75: 645–7
   PubMed Web of Science ®Google Scholar
• Shaw A. S., Ampong M. A., Rio A., McClure J., Leigh P. N., Sidhu P. S. Entristar skin‐level gastrostomy tube: primary placement with radiologic guidance in patients with amyotrophic lateral sclerosis. Radiology 2004; 233: 392–9
   PubMed Web of Science ®Google Scholar
• Thornton F. J., Fotheringham T., Alexander M., Hardiman O., McGrath F. P., Lee M. J. Amyotrophic lateral sclerosis: enteral nutrition provision – endoscopic or radiologic gastrostomy?. Radiology 2002; 224: 713–7
   PubMed Web of Science ®Google Scholar
• Scott A. G., Austin H. E. Nasogastric feeding in the management of severe dysphagia in motor neuron disease. Palliat Med 1994; 8: 45–9
   PubMedGoogle Scholar
• Bak T. H., Hodges J. R. The effects of motor neuron disease on language: further evidence. Brain Lang 2004; 89: 354–61
   PubMed Web of Science ®Google Scholar
• Cobble M. Language impairment in motor neuron disease. J Neurol Sci 1998; 160((Suppl 1))S47–52
   PubMed Web of Science ®Google Scholar
• Murphy J. Communication strategies of people with ALS and their partners. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 121–6
   PubMed Web of Science ®Google Scholar
• Borasio G. D., Voltz R., Miller R. G. Palliative Care in Amyotrophic Lateral Sclerosis. Neurol Clin 2001; 19: 829–47, In: Carver A, Foley K, editors. Palliative Care
   PubMed Web of Science ®Google Scholar
• Oliver D., Borasio G. D., Walsh D., Eds. Palliative Care in Amyotrophic Lateral Sclerosis. Oxford University Press, Oxford 2006, 2nd edn
   Google Scholar
• Mitsumoto H., Bromberg M., Johnston W., Tandan R., Byock I., Lyon M., et al. Promoting excellence in end‐of‐life care in ALS. Amyotroph Lateral Scler 2005; 6: 145–54
   PubMed Web of Science ®Google Scholar
• Sykes N., Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncology 2003; 4: 312–8
   PubMed Web of Science ®Google Scholar